Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury

Inclusion Criteria: * Age ≥ 18 and ≤ 75 years, Male or female patients * Alanine aminotransferase (ALT) ≥ 3 x upper limit of normal (ULN) and Total bilirubin (TBIL) ≤ 5 x upper limit of normal (ULN) * The Roussel Uclaf Causality Assessment Method (RUCAM) score is more than or equal to 6 points. The patients with RUCAM score of 3-5 needs to be determined by all three investigators that the liver injury is likely to be caused by drugs * The duration of the current liver injury does not exceed 6 months Exclusion Criteria: * Liver injury caused by other diseases, such as viral hepatitis, alcoholic and non-alcoholic fatty liver disease, or autoimmune liver disease * Acute liver failure or liver function decompensation, such as hepatic encephalopathy, ascites, albumin is less than 35g / L, the international standardized ratio (INR) of thrombin is more than 1.5 * Anemia or thrombocytopenia, hemoglobin is below 80 g/L, platelet count below 50,000 platelets per microliter * Serum creatinine is more than 1.5 times ULN * Severe hypokalemia, severe hypernatremia * Patients have severe uncontrolled hypertension * Severe diseases of vital organs such as heart, lung, brain, kidney, and gastrointestinal tract * Treatment with polyene phosphatidylcholine injection or magnesium isoglycyrrhizinate injection within 5 days before informed consent * Allergy or intolerance to benzyl alcohol and study drugs * With no ability to express their complaints, such as mental illness and severe neurosis patient * Pregnant or breastfeeding women, fertile women or men are reluctant to use contraception to avoid pregnancy during the trial * Participation in another trial within 3 months before informed consent * Patients who are considered by the investigator as inappropriate for the trial for other reasons